

ARLINGTON COMMUNITY SERVICES BOARD

SUBSTANCE ABUSE/MH COMMITTEE JOINT MEETING MINUTES

January 28, 2013

Members Present: Jim Mack, Charlie Baughman, Keith Whyte, Shaun Buckner, Anne Hermann, Judy Deane, Tom Quinn, Richard Smith, Betsy Greer

Members Absent: Craig Dabney, Bharati Patel, Wes Sanchez, Reina Escobar, Jenette O'Keefe

BHD Staff: Joe Bullock, Alan Orenstein

- I. BHD INTEGRATED DUAL DIAGNOSIS PROGRAM OVERVIEW-** Dr. Alan Orenstein began the meeting by welcoming members from both the MH and SA Subcommittees. Dr. Orenstein provided a brief introductory overview of the historical evolution for the treatment of co-occurring disorders as well as prevalence estimates for the MH/SA population. Dr. Orenstein also described the planning process for integrating treatment services for the Behavioral Healthcare Division which began in 2005 with extensive cross-training of MH and SA staff on the screening, identification and treatment protocol for individuals with a co-occurring MH/SA disorder. Dr. Orenstein also identified key characteristics of a treatment system capable of adequately responding to the treatment needs of co-occurring disorders. Dr. Orenstein completed his review by discussing key concepts for service development to include: staff training; consultation with state experts on the implementation of an integrated system; formulation of multidisciplinary teams and development of a fidelity scale for accurate tracking of staff competencies in this specialized area.
- II. DIFFERENTIAL TREATMENTS & OUTCOME MEASURES:** Dr. Bullock welcomed members from both committees and gave a brief overview of a variety of differential treatment approaches/concepts for three primary populations: young adults; individuals with a combination of serious mental illness (SMI) and substance dependence and consumers who are diagnosed with low to moderate mental illness and substance dependence. Dr. Bullock stated that the most common evidenced based treatments for these co-occurring disorders include: Motivational Interviewing, Cognitive Behavior therapy, Group Counseling, Medication, Health Promotion and a wide array of ancillary services. Dr. Bullock concluded his overview by discussing some of the key outcome measures that he uses to track/monitor clients receiving services.
- III. DRUG COURT PROGRAM OVERVIEW:** Dr. Bullock provided the committee with a brief historical overview of the process for the establishment of a drug court in Arlington that started back to 2001. Dr. Bullock noted that the most significant point in time was October 2011 when Chief Judge William Newman appointed a work group to explore the possibility for establishing a drug court in Arlington. This work group brought together key members from the CSB, Public Defender and the Commonwealth Attorney's offices. A much larger community stakeholder group was organized in the winter of 2012 to approve of a formal application for establishing a drug court in Arlington with the Virginia Supreme Court. Dr. Bullock reported that the application was approved in October 2012 and the Arlington Drug Court Team has continued to work on building out the infrastructure and operational guidelines for the program. Dr. Bullock concluded his presentation by stated that it is anticipated that the Arlington Drug Court Team will hold its first drug court docket on March 7, 2013.

NOTE: The next SA Committee meeting will be held on **February 25, 2013 at 7:00 pm** and will be held in the George Mason Center Conference Room next to Drewry Building- room 232.